Sort by
Items per page

Send to

Choose Destination

Search results

Items: 7


The oncogenic neurotrophin receptor tropomyosin-related kinase variant, TrkAIII.

Farina AR, Cappabianca L, Ruggeri P, Gneo L, Pellegrini C, Fargnoli MC, Mackay AR.

J Exp Clin Cancer Res. 2018 Jun 18;37(1):119. doi: 10.1186/s13046-018-0786-3. Review.


TrkAIII signals endoplasmic reticulum stress to the mitochondria in neuroblastoma cells, resulting in glycolytic metabolic adaptation.

Farina AR, Cappabianca L, Gneo L, Ruggeri P, Mackay AR.

Oncotarget. 2017 Dec 22;9(9):8368-8390. doi: 10.18632/oncotarget.23618. eCollection 2018 Feb 2.


Retrograde TrkAIII transport from ERGIC to ER: a re-localisation mechanism for oncogenic activity.

Farina AR, Cappabianca L, Ruggeri P, Gneo L, Maccarone R, Mackay AR.

Oncotarget. 2015 Nov 3;6(34):35636-51. doi: 10.18632/oncotarget.5802.


Gelatinase B/MMP-9 in Tumour Pathogenesis and Progression.

Farina AR, Mackay AR.

Cancers (Basel). 2014 Jan 27;6(1):240-96. doi: 10.3390/cancers6010240.


The alternative TrkAIII splice variant targets the centrosome and promotes genetic instability.

Farina AR, Tacconelli A, Cappabianca L, Cea G, Panella S, Chioda A, Romanelli A, Pedone C, Gulino A, Mackay AR.

Mol Cell Biol. 2009 Sep;29(17):4812-30. doi: 10.1128/MCB.00352-09. Epub 2009 Jun 29.


Reconstitution of TIMP-2 expression in SH-SY5Y neuroblastoma cells by 5-azacytidine is mediated transcriptionally by NF-Y through an inverted CCAAT site.

Cappabianca L, Farina AR, Tacconelli A, Mantovani R, Gulino A, Mackay AR.

Exp Cell Res. 2003 Jun 10;286(2):209-18.


Supplemental Content

Loading ...
Support Center